Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Inflammation
Erschienen in: Inflammation 4/2013

01.08.2013

Adipocytokine Levels in Obese and Non-obese Subjects: an Observational Study

verfasst von: Giuseppe Derosa, Elena Fogari, Angela D’Angelo, Lucio Bianchi, Aldo Bonaventura, Davide Romano, Pamela Maffioli

Erschienen in: Inflammation | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

We evaluated the levels of some inflammatory adipocytokines in 363 obese and 365 non-obese subjects. We measured: body mass index (BMI), waist circumference (WC), fasting plasma glucose, fasting plasma insulin (FPI), homeostasis model assessment (HOMA) index, blood pressure, lipid profile, retinol binding protein-4 (RBP-4), vaspin, omentin-1, leptin, interleukin-6 (IL-6), visfatin, resistin, adiponectin (ADN), adipsin, tumor necrosis factor-α (TNF-α), and high sensitivity C-reactive protein (Hs-CRP). We observed higher BMI, WC, FPI, HOMA index, TC, LDL-C, RBP-4, leptin, IL-6, adipsin, Hs-CRP, vaspin, resistin and TNF-α levels, and lower visfatin, and ADN levels in obese compared to non-obese subjects. Higher WC correlated with lower ADN and visfatin levels, and higher vaspin levels. Higher HOMA index correlated with higher resistin, adipsin, RBP-4, and leptin concentrations, while higher leptin levels correlated with higher TNF-α, Hs-CRP, and IL-6 concentration, and lower ADN values. We confirmed obese subjects’ predisposition to develop dysmetabolic disease and hormonal dysfunctions.
Literatur
1.
Van Gaal, L.F., I.L. Mertens, and C.E. De Block. 2006. Mechanisms linking obesity with cardiovascular disease. Nature 444: 875–880.PubMedCrossRef
2.
Stevens, J., J. Cai, E.R. Pamuk, D.F. Williamson, M.J. Thun, and J.L. Wood. 1998. The effect of age on the association between body-mass index and mortality. The New England Journal of Medicine 338(1): 1–7.PubMedCrossRef
3.
Laimer, M., S. Kaser, M. Kranebitter, A. Sandhofer, G. Mühlmann, H. Schwelberger, H. Weiss, J.R. Patsch, and C.F. Ebenbichler. 2005. Effect of pronounced weight loss on the nontraditional cardiovascular risk marker matrix metalloproteinase-9 in middle-aged morbidly obese women. International Journal of Obesity 29(5): 498–501.PubMed
4.
Ahima, R.S. 2000. Leptin and the neuroendocrinology of fasting. Frontiers of Hormone Research 26: 42–56.PubMedCrossRef
5.
Flier, J.S. 2004. Obesity wars: molecular progress confronts an expanding epidemic. Cell 116(2): 337–350.PubMedCrossRef
6.
Hausman, G.J., and R.L. Richardson. 2004. Adipose tissue angiogenesis. Journal of Animal Science 82(3): 925–934.PubMed
7.
Rupnick, M.A., D. Panigrahy, C.Y. Zhang, S.M. Dallabrida, B.B. Lowell, R. Langer, and M.J. Folkman. 2002. Adipose tissue mass can be regulated through the vasculature. Proceedings of the National Academy of Sciences of the United States of America 99(16): 10730–10735.PubMedCrossRef
8.
Trayhurn, P., and I.S. Wood. 2004. Adipokines: inflammation and the pleiotropic role of white adipose tissue. British Journal of Nutrition 92(3): 347–355.PubMedCrossRef
9.
Weisberg, S.P., D. McCann, M. Desai, M. Rosenbaum, R.L. Leibel, and A.W. Ferrante Jr. 2003. Obesity is associated with macrophage accumulation in adipose tissue. The Journal of Clinical Investigation 112(12): 1796–1808.PubMed
10.
Derosa, G., I. Ferrari, A. D'Angelo, C. Tinelli, S.A. Salvadeo, L. Ciccarelli, M.N. Piccinni, A. Gravina, F. Ramondetti, P. Maffioli, and A.F. Cicero. 2008. Matrix metalloproteinase-2 and -9 levels in obese patients. Endothelium 15(4): 219–224.PubMedCrossRef
11.
Sluijter, J.P., D.P. de Kleijn, and G. Pasterkamp. 2006. Vascular remodeling and protease inhibition—bench to bedside. Cardiovascular Research 69(3): 595–603.PubMedCrossRef
12.
World Health Organization. 1997. Obesity: preventing and managing the global epidemic. Report of WHO Consultation on Obesity. Geneva: WHO.
13.
American Diabetes Association. 2001. Screening for diabetes (Position Statement). Diabetes Care 24: S21–S24.
14.
European Diabetes Policy Group 1999. 1999. A desktop guide to type 2 diabetes mellitus. Diabetic Medicine 16(9): 716–730.CrossRef
15.
Heding, L.G. 1972. Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia 8(4): 260–266.PubMedCrossRef
16.
Matthews, D.R., J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, and R.C. Turner. 1985. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412–419.PubMedCrossRef
17.
Wallace, T.M., J.C. Levy, and D.R. Matthews. 2004. Use and abuse of HOMA modeling. Diabetes Care 27: 1487–1495.PubMedCrossRef
18.
Klose, S., and K. Borner. 1978. Enzymatische Bestimmung des Gesamtcholesterins mit dem [Enzymatic dosage of total cholesterolemia by Greiner Selective Analyzer (GSA II)]. Journal of Clinical Chemistry and Clinical Biochemistry 15: 121–130.
19.
Wahlefeld, A.W. 1974. Triglycerides determination after enzymatic hydrolysis. In Methods of enzymatic analysis, 2 English edth ed, ed. H.U. Bergmeyer, 18–31. New York: Academic Press.
20.
Havel, R.J., H.A. Eder, and J.H. Bragdon. 1955. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. The Journal of Clinical Investigation 34: 1345–1353.PubMedCrossRef
21.
Friedewald, W.T., R.I. Levy, and D.S. Fredrickson. 1972. Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry 18: 499–502.PubMed
22.
Takebayashi, K., M. Suetsugu, S. Wakabayashi, Y. Aso, and T. Inumai. 2007. Retinol binding protein-4 and clinical features of type 2 diabetes patients. Journal of Clinical Endocrinology and Metabolism 92: 2712–2719.PubMedCrossRef
23.
Hida, K., J. Wada, J. Eguchi, H. Zhang, M. Baba, A. Seida, I. Hashimoto, T. Okada, A. Yasuhara, A. Nakatsuka, K. Shikata, S. Hourai, J. Futami, E. Watanabe, Y. Matsuki, R. Hiramatsu, S. Akagi, H. Makino, and Y.S. Kanwar. 2005. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proceedings of the National Academy of Sciences 102: 10610–10615.CrossRef
24.
De Souza Batista, C.M., R.Z. Yang, M.J. Lee, N.M. Glynn, D.Z. Yu, J. Pray, K. Ndubuizu, S. Patil, A. Schwartz, M. Kligman, S.K. Fried, D.W. Gong, A.R. Shuldiner, T.I. Pollin, and J.C. McLenithan. 2007. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 56(6): 1655–1661.PubMedCrossRef
25.
26.
Korner, A., A. Garten, M. Bluher, R. Tauscher, J. Kratzsch, and W. Kiess. 2007. Molecular characteristics of serum visfatin and differential detection by immunoassays. Journal of Clinical Endocrinology and Metabolism 92: 4783–4791.PubMedCrossRef
27.
Yamauchi, T., J. Kamon, H. Waki, Y. Terauchi, N. Kubota, K. Hara, Y. Mori, T. Ide, K. Murakami, N. Tsuboyama-Kasaoka, O. Ezaki, Y. Akanuma, O. Gavrilova, C. Vinson, M.L. Reitman, H. Kagechika, K. Shudo, M. Yoda, Y. Nakano, K. Tobe, R. Nagai, S. Kimura, M. Tomita, P. Froguel, and T. Kadowaki. 2001. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nature Medicine 7: 941–946.PubMedCrossRef
28.
Yannakoulia, M., N. Yiannakouris, S. Bluher, A.L. Matalas, D. Klimis-Zacas, and C.S. Mantzoros. 2003. Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. Journal of Clinical Endocrinology and Metabolism 88: 1730–1736.PubMedCrossRef
29.
Misra, A., and A. Garg. 1996. Leptin: its receptor and obesity. Journal of Investigative Medicine 44: 540–548.PubMed
30.
Cook, K.S., D.L. Groves, H.Y. Min, and B.M. Spiegelman. 1985. Proceedings of the National Academy of Sciences of the United States of America 82: 6480–6484.PubMedCrossRef
31.
Zhang, M., and K. Tracey. 1988. The cytokine handbook, 3rd ed. San Diego: Academic Press.
32.
Rifai, N., R.P. Tracy, and P.M. Ridker. 1999. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clinical Chemistry 45(12): 2136–2141.PubMed
33.
Gu, P., and A. Xu. 2013. Interplay between adipose tissue and blood vessels in obesity and vascular dysfunction. Reviews in Endocrine & Metabolic Disorders. doi:10.​1007/​s11154-012-9230-8.
34.
Yang, Q., T.E. Graham, N. Mody, F. Preitner, O.D. Peroni, J.M. Zabolotny, K. Kotani, L. Quadro, and B.B. Kahn. 2005. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 436(7049): 356–362.PubMedCrossRef
35.
Hida, K., J. Wada, J. Eguchi, H. Zhang, M. Baba, A. Seida, I. Hashimoto, T. Okada, A. Yasuhara, A. Nakatsuka, K. Shikata, S. Hourai, J. Futami, E. Watanabe, Y. Matsuki, R. Hiramatsu, S. Akagi, H. Makino, and Y.S. Kanwar. 2005. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proceedings of the National Academy of Sciences of the United States of America 102(30): 10610–10615.PubMedCrossRef
36.
Youn, B.S., N. Klöting, J. Kratzsch, N. Lee, J.W. Park, E.S. Song, K. Ruschke, A. Oberbach, M. Fasshauer, M. Stumvoll, and M. Blüher. 2008. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes 57(2): 372–377.PubMedCrossRef
37.
El-Mesallamy, H.O., D.H. Kassem, E. El-Demerdash, and A.I. Amin. 2011. Vaspin and visfatin/Nampt are interesting interrelated adipokines playing a role in the pathogenesis of type 2 diabetes mellitus. Metabolism 60(1): 63–70.PubMedCrossRef
38.
Yang, R.Z., M.J. Lee, H. Hu, J. Pray, H.B. Wu, B.C. Hansen, A.R. Shuldiner, S.K. Fried, J.C. McLenithan, and D.W. Gong. 2006. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. American Journal of Physiology, Endocrinology and Metabolism 290(6): E1253–E1261.CrossRef
39.
Schäffler, A., M. Neumeier, H. Herfarth, A. Fürst, J. Schölmerich, and C. Büchler. 2005. Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochimica et Biophysica Acta 1732(1–3): 96–102.PubMedCrossRef
40.
Kralisch, S., J. Klein, M. Bluher, R. Paschke, M. Stumvoll, and M. Fasshauer. 2005. Therapeutic perspectives of adipocytokines. Expert Opinion on Pharmacotherapy 6: 863–872.PubMedCrossRef
41.
Fukuhara, A., M. Matsuda, M. Nishizawa, K. Segawa, M. Tanaka, K. Kishimoto, Y. Matsuki, M. Murakami, T. Ichisaka, H. Murakami, E. Watanabe, T. Takagi, M. Akiyoshi, T. Ohtsubo, S. Kihara, S. Yamashita, M. Makishima, T. Funahashi, S. Yamanaka, R. Hiramatsu, Y. Matsuzawa, and I. Shimomura. 2005. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307(5708): 426–430.PubMedCrossRef
42.
Hug, C., and H.F. Lodish. 2005. Medicine. Visfatin: a new adipokine. Science 307(5708): 366–367.PubMedCrossRef
43.
Li, R.Z., X.Y. Ma, X.F. Hu, S.X. Kang, S.K. Chen, K. Cianflone, and H.L. Lu. 2012. Elevated visfatin levels in obese children are related to proinflammatory factors. Journal of Pediatric Endocrinology & Metabolism 14: 1–8.CrossRef
44.
Olszanecka-Glinianowicz, M., P. Kocełak, M. Nylec, J. Chudek, and B. Zahorska-Markiewicz. 2012. Circulating visfatin level and visfatin/insulin ratio in obese women with metabolic syndrome. Archives of Medical Science 8(2): 214–218.PubMedCrossRef
45.
Azuma, K., S. Oguchi, Y. Matsubara, T. Mamizuka, M. Murata, H. Kikuchi, K. Watanabe, F. Katsukawa, H. Yamazaki, A. Shimada, and T. Saruta. 2004. Novel resistin promoter polymorphisms: association with serum resistin level in Japanese obese individuals. Hormone and Metabolic Research 36(8): 564–570.PubMedCrossRef
46.
Bouchard, L., S.J. Weisnagel, J.C. Engert, T.J. Hudson, C. Bouchard, M.C. Vohl, and L. Pérusse. 2004. Human resistin gene polymorphism is associated with visceral obesity and fasting and oral glucose stimulated C-peptide in the Québec Family Study. Journal of Endocrinological Investigation 27(11): 1003–1009.PubMed
47.
McTernan, P.G., F.M. Fisher, G. Valsamakis, R. Chetty, A. Harte, C.L. McTernan, P.M. Clark, S.A. Smith, A.H. Barnett, and S. Kumar. 2003. Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. Journal of Clinical Endocrinology and Metabolism 88(12): 6098–6106.PubMedCrossRef
48.
Ohmori, R., Y. Momiyama, R. Kato, H. Taniguchi, M. Ogura, M. Ayaori, H. Nakamura, and F. Ohsuzu. 2005. Associations between serum resistin levels and insulin resistance, inflammation, and coronary artery disease. Journal of the American College of Cardiology 46(2): 379–380.PubMedCrossRef
49.
Jackson, M.B., and R.S. Ahima. 2006. Neuroendocrine and metabolic effects of adipocyte-derived hormones. Clinical Science 110: 143–152.PubMedCrossRef
50.
Berg, A.H., T.P. Combs, and P.E. Scherer. 2002. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends in Endocrinology and Metabolism 13: 84–89.PubMedCrossRef
51.
Bouskila, M., U.B. Pajvani, and P.E. Scherer. 2005. Adiponectin: a relevant player in PPARγ-agonist mediated improvements in hepatic insulin sensitivity? International Journal of Obesity and Related Metabolic Disorders 29(Suppl. 1): S17–S23.CrossRef
52.
Maeda, N., I. Shimomura, K. Kishida, H. Nishizawa, M. Matsuda, H. Nagaretani, N. Furuyama, H. Kondo, M. Takahashi, Y. Arita, R. Komuro, N. Ouchi, S. Kihara, Y. Tochino, K. Okutomi, M. Horie, S. Takeda, T. Aoyama, T. Funahashi, and Y. Matsuzawa. 2002. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nature Medicine 8: 731–737.PubMedCrossRef
53.
Berg, A.H., T.P. Combs, X. Du, M. Brownlee, and P.E. Scherer. 2001. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nature Medicine 7: 947–953.PubMedCrossRef
54.
Cook, K.S., H.Y. Min, D. Johnson, R.J. Chaplinsky, J.S. Flier, C.R. Hunt, and B.M. Spiegelman. 1987. Adipsin: a circulating serine protease homolog secreted by adipose tissue and sciatic nerve. Science 237(4813): 402–405.PubMedCrossRef
55.
Uysal, K.T., S.M. Wiesbrock, M.W. Marino, and G.S. Hotamisligil. 1997. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 389(6651): 610–614.PubMedCrossRef
56.
Hotamisligil, G.S., N.S. Shargill, and B.M. Spiegelman. 1993. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259(5091): 87–91.PubMedCrossRef
57.
Hotamisligil, G.S. 1999. The role of TNF-alpha and TNF receptors in obesity and insulin resistance. Journal of Internal Medicine 245: 621–625.PubMedCrossRef
Metadaten
Titel
Adipocytokine Levels in Obese and Non-obese Subjects: an Observational Study
verfasst von
Giuseppe Derosa
Elena Fogari
Angela D’Angelo
Lucio Bianchi
Aldo Bonaventura
Davide Romano
Pamela Maffioli
Publikationsdatum
01.08.2013
Verlag
Springer US
Erschienen in
Inflammation / Ausgabe 4/2013
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-013-9620-4

Weitere Artikel der Ausgabe 4/2013

Inflammation 4/2013 Zur Ausgabe

OriginalPaper

Comprehensive Profiling of Peripheral Immune Cells and Subsets in Patients with Intermittent Allergic Rhinitis Compared to Healthy Controls and After Treatment with Glucocorticoids

OriginalPaper

C-Reactive Protein Measurements as a Marker of the Severity of Chronic Obstructive Pulmonary Disease Exacerbations

OriginalPaper

Assessment of Oxidative, Inflammatory, and Fibrinolytic Biomarkers and DNA Strand Breakage in Hypercholesterolemia

OriginalPaper

Inflammatory Markers in the Second Trimester Prior to Clinical Onset of Preeclampsia, Intrauterine Growth Restriction, and Spontaneous Preterm Birth

Erratum

Erratum to: Suppression of MAPK and NF-κB Pathways by Limonene Contributes to Attenuation of Lipopolysaccharide-Induced Inflammatory Responses in Acute Lung Injury

OriginalPaper

Increased Fecal Levels of Chromogranin A, Chromogranin B, and Secretoneurin in Collagenous Colitis

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise